Amgen Hedges On Sandoz's High Court Biosimilar Petition
Amgen on Tuesday said the U.S. Supreme Court should reject Sandoz's bid to revisit one part of a landmark Federal Circuit ruling on the obligations of biosimilar makers, but added that...To view the full article, register now.
Already a subscriber? Click here to view full article